Skip to main content
. 2022 Dec 16;75(1):19–31. doi: 10.1007/s43440-022-00440-6

Table 2.

Aripiprazole affinity for human receptors

Types Affinity Affinity Ki (nmol/L) Biological action Pharmacological action
Dopamine receptors
 D2  +  +  +  +  Very high 0.34# Partial agonist Yes
 D3  +  +  +  +  Very high 0.8# Unknown
 D4  +  Moderate 44# Unknown
Serotonin receptors
 5-HT2B  +  +  +  +  Very high 0.36## Inverse agonist Unknown
 5-HT1A  +  +  +  High 1.7# Partial agonist Unknown
 5-HT2A  +  +  Moderate 3.4# Antagonist/partial agonist Yes
 5-HT2C  +  Limited 15# Partial agonist Unknown
 5-HT7  +  +  +  High 39# (10##) Partial agonist Unknown
 5-HT1D  +  +  Moderate 68## Antagonist Unknown
 5-HT6  +  Limited 570## Antagonist Unknown
 5-HT1B  +  Limited 830## Antagonist Unknown
Noradrenaline receptors
 α1A  +  +  Moderate 57# (26##) Antagonist No
 α1B  +  +  Moderate 35## Antagonist No
 α2C  +  +  Moderate 38## Antagonist No
 α2A  +  +  Moderate 74## Antagonist No
 α2B  +  Limited 103## Antagonist No
Histamine receptors
 H1  +  +  Moderate 61# (25##) Antagonist No

Ki the binding affinities were assessed in vitro

#Abilify Maintena prescribing information [ABILIFY MAINTENA—Accessdata.fda.gov]

##SHAPIRO et al. 2003 [121]